Navigating the Balance: Key Takeaways from the 2023 CHEST Guidelines on Perioperative Antithrombotic Therapy

1. Introduction: The High-Stakes Balancing Act

In clinical practice, the perioperative management of antithrombotic therapy remains a high-stakes balancing act. Clinicians are tasked with navigating a narrow therapeutic window: mitigating the risk of devastating arterial thromboembolism (ATE) or venous thromboembolism (VTE) while simultaneously minimizing the potential for life-threatening surgical bleeding.

As the population ages, the prevalence of antithrombotic use continues to rise. Current data suggests that approximately 15% to 20% of patients on long-term anticoagulation—and 10% to 15% of those with coronary stents—require surgery or an invasive procedure annually. The 2022/2023 American College of Chest Physicians (CHEST) guidelines provide a rigorous, evidence-based framework for managing Vitamin K Antagonists (VKAs), Direct Oral Anticoagulants (DOACs), and antiplatelet agents, moving the needle toward simplified, safer perioperative care.

2. The End of "Bridging" for Everyone: A Paradigm Shift

"Heparin bridging"—the administration of a short-acting anticoagulant (typically LMWH or UFH) for an 8- to 10-day period during VKA interruption—was once considered a mandatory safety net. However, the 2023 update signals a major departure from this practice for most patients.

The guidelines issue two Strong Recommendations that simplify management:

1. Against heparin bridging in patients with Atrial Fibrillation (PICO 6).
2. For continuing VKA therapy without interruption in patients undergoing pacemaker or ICD implantation (PICO 14).

This shift is rooted in evidence from the BRIDGE and PERIOP-2 trials, which clarified why bridging is being phased out:

1. Lack of Efficacy: Bridging does not significantly reduce the risk of stroke or ATE compared to simple interruption.
2. Increased Harm: Bridging is associated with a threefold increased risk of major bleeding.
3. Complex Care Transitions: Avoiding bridging reduces the complexity of care and the potential for dosing errors during the perioperative transition.

3. Mastering the Vitamin K Antagonist (Warfarin) Timeline

For elective procedures where a VKA must be interrupted to normalize the INR, precision in timing is essential.

Warfarin Management Protocol

Stage	Action	Timing/Instruction
Interruption	Stop Warfarin	5 days before the surgery/procedure.
Resumption	Restart Warfarin	Within 24 hours post-op (evening of or day after).
Dosing	Resume Maintenance	Use the patient's usual maintenance dose; do not double-dose.

Note on Preoperative Vitamin K: The guidelines suggest against the routine use of preoperative Vitamin K to normalize the INR unless it remains >1.5 one to two days before surgery (PICO 4). This caution is due to the potential for Vitamin K to induce a state of resistance to post-operative re-anticoagulation, complicating the return to therapeutic levels.

4. The "New Normal": Managing DOACs (Apixaban, Dabigatran, Edoxaban, Rivaroxaban)

The management of DOACs is dictated by their predictable pharmacokinetics, specifically their 9- to 14-hour half-lives. Unlike Warfarin, DOACs have a rapid onset and offset, reaching peak anticoagulant effect within just 1 to 3 hours of the first dose. This rapid onset is why premature resumption is clinically dangerous.

Pharmacokinetic Interruption Rules:

• Low-to-moderate-bleed-risk: Stop the DOAC 1 day (30–36 hours) before surgery.
• High-bleed-risk: Stop the DOAC 2 days (60–68 hours) before surgery. This window ensures the drug has cleared for 4 to 5 half-lives, resulting in minimal to no residual effect at the time of incision.

The Dabigatran/Renal Exception: Because Dabigatran is primarily cleared by the kidneys, patients with a CrCl < 50 mL/min undergoing high-risk procedures require 4 full days of interruption to ensure safety.

Implementation Note: Routine preoperative laboratory testing (e.g., anti-factor Xa) is suggested against (PICO 28), as standard tests are often insensitive and standardized interruption windows are highly reliable.

5. Antiplatelet Management: Aspirin, P2Y12 Inhibitors, and Stents

Antiplatelet management requires a nuanced assessment of the surgical site and the patient’s cardiac history. For most elective non-cardiac surgeries, the guidelines suggest continuing Aspirin (PICO 29a). However, a critical exception exists: Aspirin should be modified or interrupted for intracranial or spinal surgeries due to the catastrophic risk of localized bleeding in enclosed spaces.

P2Y12 Inhibitor Interruption Windows:

• Ticagrelor: 3–5 days.
• Clopidogrel: 5 days.
• Prasugrel: 7 days.

Patients with Coronary Stents: Management is stratified by the timing of the stent placement (PICO 37–40):

• Stents < 6–12 weeks: This is a high-risk period for stent thrombosis. Either continue dual antiplatelet therapy (DAPT) or stop one agent within 7–10 days of surgery based on bleed risk.
• Stents 3–12 months: Generally, suggest stopping the P2Y12 inhibitor while continuing Aspirin throughout the perioperative period.
• Elective Delay: If a patient requires mandatory DAPT, elective surgery should be delayed to avoid the high mortality associated with perioperative stent thrombosis.

6. Minor Procedures: When Therapy Doesn't Need to Stop

For minor procedures where bleeding is easily controlled or localized, the risk of a thromboembolic event from stopping therapy often outweighs the benefit of interruption.

Category	Procedure Examples	Clinical Instruction
Dental	Extractions, root canals	Continue therapy. For VKAs, use 10 mL of a 5% tranexamic acid mouthwash solution pre- and post-op.
Dermatologic	Small skin cancer resections, biopsies	Continue therapy; interruption is generally not required for small lesions.
Ophthalmologic	Cataract surgery (phaco)	Continue therapy; these are largely avascular procedures.

7. Individualized Risk Stratification: The Framework

These guidelines serve as a starting point and must be integrated with clinical judgment.

High Thromboembolic Risk Criteria:

• Mechanical Heart Valves: Mitral valves, older-generation valves (caged ball or tilting-disc), or recent stroke/TIA (<3 months).
• Atrial Fibrillation: CHA₂DS₂-VASc score ≥ 7, or mitral valve disease with major risk factors for stroke.
• VTE: Recent event (<1 month) or severe thrombophilia (e.g., Antiphospholipid Syndrome).

High-Bleed-Risk Surgery & Neuraxial Considerations: High-risk procedures include intracranial, spinal, major orthopedic, and vascular surgeries. A critical safety point is the use of neuraxial (spinal/epidural) anesthesia. The risk of epidural hematoma leading to permanent paralysis is a primary reason for strict adherence to interruption windows and the avoidance of premature resumption.

8. Conclusion: Actionable Insights for the Clinical Team

The 2023 CHEST guidelines transition perioperative care toward evidence-based simplification. The three most impactful shifts are the significant reduction in heparin bridging, the adoption of standardized 1- to 2-day DOAC windows, and the continuation of VKA therapy for cardiac device implantations.

Final Takeaway Perioperative safety is a product of multidisciplinary coordination. Uncoordinated care between the surgeon, cardiologist, and pharmacist carries an avoidable 0.5–1.0% excess risk of stroke and a 3–6% excess risk of major bleeding. The use of these standardized, 4–5 half-life-based protocols is the most effective intervention to prevent these outcomes.

Disclaimer: These guidelines are intended for elective, non-urgent surgery only and do not replace professional medical judgment or advice for individual clinical cases.